Speaker alumni

Rob Kapito is President and a Director of BlackRock, a member of BlackRock’s Global Executive Committee and Chairman of the Global Operating Committee. He is responsible for day-to-day oversight of all BlackRock’s key operating units including Investment Strategies, Client Businesses, Technology & Operations, and Risk & Quantitative Analysis. Mr. Kapito is also a Director of iShares Inc.

‍

Prior to assuming his current responsibilities in 2007, Mr. Kapito served as Head of BlackRock’s Portfolio Management Group. In this role, he was responsible for overseeing all portfolio management within BlackRock, including the Fixed Income, Equity, Liquidity, and Alternative Investment Groups. Prior to founding BlackRock in 1988, Mr. Kapito was a Vice President in the Mortgage Products Group at The First Boston Corporation.

‍

Mr. Kapito serves as a member of the Board of Trustees of the University of Pennsylvania and the Harvard Business School Board of Dean’s Advisors. He is also President of the Board of Directors for the Hope & Heroes Children’s Cancer Fund. Mr. Kapito is the recipient of the 2009 Joseph Wharton Leadership Award, the Marine Corps-Law Enforcement Foundation’s 2010 Semper Fidelis Award and is a frequent public speaker on best practices in investment management.

‍

Mr. Kapito earned a BS degree in economics from the Wharton School of the University of Pennsylvania in 1979, and an MBA degree from Harvard Business School in 1983.

‍

Scott Bessent serves as Chief Executive Officer and Chief Investment Officer for Key Square Capital Management, a New York-based investment partnership that he founded in 2015. Mr. Bessent was Chief Investment Officer for Soros Fund Management (SFM), the investment vehicle for the Soros Family and their foundations, from 2011 to 2015. He has been a well-known investor in the macro space for more than two decades.

‍

From 1991 to 2000, Mr. Bessent was managing partner of SFM’s London office, including the period of the British Pound devaluation.  He was previously associated with Brown Brothers Harriman, The Olayan Group, Kynikos Associates and Protégé Partners.

‍

From 2006 to 2010, Mr. Bessent was an adjunct professor at Yale University, where he taught economic history.  He is profiled in the book on macro investors, Inside the House of Money, and features prominently in Sebastian Mallaby’s history of hedge funds, More Money than God. He is a frequent speaker on economic and investment panels.

‍

In 2017, Mr. Bessent published two articles in The International Economy magazine: one on the suppressing effects of low real interest rates on volatility, and one discussing whether other countries are at risk for “Japan Disease.”

‍

Mr. Bessent resides in Manhattan with his spouse and two children.  He is a trustee of Rockefeller University where he chairs the investment committee and is a member of the executive committee, the Yale University Council and Classical American Homes Preservation Trust.  Mr. Bessent is a member of the Council on Foreign Relations. He holds a B.A. degree from Yale University.

Ravi is the Founder and Chief Investment Officer of Azora Capital, a financial services sector hedge fund launched in 2017. Ravi and his team are passionate about financials and have dedicated their careers to researching the space. Together they employ a deep fundamental strategy that allocates capital to the most actionable names across financial subsectors (banks, fintech, payments, brokers, asset managers, real estate, etc.) to generate alpha through distinct market cycles.

Prior to forming Azora, Ravi was a Partner and Head of U.S. Financials at Samlyn Capital from 2007 to 2016. Ravi was a Financial Services Analyst at Sigma Capital from 2003 to 2006 and began his career as an Investment Banking Analyst in Goldman Sachs' Financial Institutions Group.

Ravi earned an A.B. in Economics from Dartmouth College. Currently, he serves as Co-President of the Board of Trustees of Morristown-Beard School, his alma mater.

Mark Nelson is Chairman and Co-founder of Caledonia, a specialist global investment manager founded in 1992 and based in Sydney, Australia. Mark was educated at the Universities of Melbourne, and Cambridge, receiving his Doctorate in 1986.

‍

Dr Nelson has over 30 years experience working in Australian and International investment and equity markets, analysing and assessing the business models of global companies in a wide variety of industries.

‍

He is currently Chairman of Art Exhibitions Australia, a Director of Kaldor Public Art Projects, and Chairman of Cricket NSW Foundation. He is also a governor of the Florey Institute of Neuroscience,a Director of the MindGardens Neuroscience Alliance, and a Director of Telix Pharmaceuticals. He serves on the International Council of the Tate Museums in London, and the Directors Council of The Getty Museum in Los Angeles and a Trustee of The Sydney Swans Foundation. Previously he was Vice President of the Board of Trustees of the Art Gallery of New South Wales and a Trustee of the Art Gallery of New South Wales Foundation.

Todd Guyot is a Portfolio Manager for the Regal Australian Small Companies Fund. Prior to joining Regal in November 2014, Todd was Head of Growth and Small Companies at Moelis Australia, where he was recognised by the Wall Street Journal as Asia’s Best Technology Analyst in 2013. A specialist small companies investor with over 22 years’ experience, Todd was Head of Small Companies and Growth at BNP Paribas prior to Moelis and Head of Small Company research at Burdett, Buckeridge & Young prior to that.

‍

Todd holds a Graduate Diploma of Applied Finance & Investment from the Securities Institute of Australia and has completed an Associate Course majoring in Accounting at the Australian Society of Accountants in Sydney. Todd also holds a Bachelor of Economics from Macquarie University.

Jeremy founded Terra Capital In 2010 launching the long only Terra Capital Global Natural Resources Fund. The fund has delivered strong performance resulting in Terra Capital becoming one of Australia’s longest running open ended global resources fund. 

‍

Jeremy formally worked at RAB Capital’s Special Situations Fund, a US $2.5B long/short strategy focused on mining and energy. The fund was rated the “Best Energy and Natural Resource Fund” by Hedge Fund Review and ranked No.1 in Barron’s Hedge Fund 50 Global rankings in 2007, during Jeremy’s tenure. Prior to RAB Jeremy worked at Western Australian corporate advisory firm Azure Capital.

Professor Alex Brown is the Professor of Indigenous Genomics at The Kids Research Institute Australia and The Australian National University. He is an internationally leading Aboriginal clinician/researcher (Yuin Nation) who has worked his entire career in Aboriginal health in the provision of public health services, infectious diseases and chronic disease care, health care policy and research. He has family connections to Nowra, Wreck Bay and Wallaga Lake on the far south coast of NSW.

‍
Alex was the Aboriginal Health Equity Theme Leader SAHMRI from 2013 – 2023 and has been a Professor of Medicine at the University of Adelaide since 2019.
He has established three highly regarded research groups over the last 15 years and has built a career spanning public health, quantitative clinical epidemiology, mixed-method health service research, qualitative research, and implementation science, with an increasing focus on novel clinical trials in cardiometabolic disease within Indigenous communities.  

‍
In March 2023 he was the first Indigenous scientist appointed to the CSIRO Board.

‍

‍

Peter founded Cooper Investors in 2001. Cooper Investors is a specialist equities fund manager with funds under management of approximately A$13.2 billion. As Chief Investment Officer, Peter created and implemented the firm’s investment philosophy which is applied across the international, domestic and Asian equities strategies.

As Chief Investment Officer, Peter created and implemented the firm’s VoF investment philosophy which is applied across the international and domestic equities strategies. He is responsible for mentoring investment team members and the standardisation and integration of the process across the investment teams.

Peter has over 30 years of investment management experience. In 1987, he joined the NSW State Superannuation Investment and Management Corporation as a specialist industry analyst and progressed to Deputy Portfolio Manager of the $7bn portfolio. In 1993, Peter ran the Australian equities portfolio for BNP and then joined Merrill Lynch Investment Managers (formally Mercury Asset Management) where he worked for 7 years, culminating in his position as Head of Australian Equities and Managing Director, where he oversaw a team managing $7.5bn in Australian equities.

Cooper Investors is a relationship-driven business and is committed to developing partnerships with organisations that share the Cooper Investors core values and their focus on creating shareholder value. Peter is highly regarded for his passion, integrity, and purpose.

Martin Hughes founded Toscafund Asset Management LLP in 2000. Prior to founding Toscafund, he was Chairman of Tiger Management Corporation Europe (1997-2000) and Global Head of Financials. Prior to joining Tiger, Martin worked at Credit Lyonnais Laing (1987-1997) where he specialised in researching banks, achieving a number 1 analyst ranking in 1992, becoming Head of UK Research in 1995 and Deputy Chief Executive in 1996. Previously, he worked at Barclays Investment Management and Panmure Gordon as a banks sector research analyst. Martin graduated with an honours degree in Economics from Birmingham University in 1983.

David joined Paradice as a Portfolio Manager/Analyst in 2012. David has considerable experience across all sectors and market caps within the Australian equity market. Prior to joining Paradice, he was a senior analyst covering small and mid cap companies in Macquarie Equities research team.

‍

David has over 17 years’ industry experience and holds a Bachelor of Commerce with majors in Economics and Finance.

Kara is a Managing Partner at Upfront Ventures, the largest venture capital firm based in Los Angeles. Some of her notable investments include Parachute Home, Time by Ping, Endgame, Writer, Open Raven, Britive, and Fleetsmith (acquired by Apple in 2020). Over 50% of her portfolio is led by women CEOs. Kara is also a founding member of All Raise, a VC-led group dedicated to increased diversity in funders and founders and is a founder of LA’s women’s soccer team, Angel City Football Club.

‍

Before Upfront, Kara co-founded the children's e-commerce company Moonfrye and also spent seven years at IAC where she co-headed the M&A group and acted as the Senior Vice President and General Manager of Urbanspoon and Citysearch. During her tenure at IAC she led the initial investment in Tinder. Earlier in her career, she also spent time at Morgan Stanley, Microsoft, and Battery Ventures.

‍

She received her AB in Politics from Princeton University and her MBA from Stanford University. Kara resides in Los Angeles with her husband and three daughters.

‍

Lawrence Gozlan is a leading biotechnology investor and advisor, he is the Chief Investment Officer and Founder of Scientia Capital, a specialised global investment fund focused exclusively in life sciences.

‍

Scientia was founded to provide high level expertise and to manage investments for high net worth individuals, family offices and institutional investors wanting exposure to the life sciences industry. Prior to this, Mr Gozlan was responsible for the largest biotechnology investment portfolio in Australia as the institutional biotechnology analyst at QIC (“the Queensland Investment Corporation”), an investment fund with over $60 billion under management. He previously worked as the senior biotechnology analyst in the equities team at Foster Stockbroking, and gained senior corporate finance experience advising life science companies at Deloitte. Mr Gozlan is a Non-Executive Director of Opthea Limited, a public biotechnology company listed on the ASX. Mr Gozlan holds a Bachelor of Science with Honors in microbiology and immunology from the University of Melbourne.

Raphael Arndt was appointed as the Chief Investment Officer of the Future Fund in 2014.

‍

He leads a multi-disciplinary investment team, managing more than A$140 billion, making investments across all asset classes and geographies.

‍

In particular, he focusses on the Fund’s “joined up” investment process, bringing together top down macro views and bottom up sector opportunities to construct the best overall portfolio.

‍

This involves managing investments for Australia’s sovereign wealth fund, the Future Fund, and four additional funds, including the Medical Research Future Fund, which will be one of the largest medical research funds in the world when fully funded.

‍

Raphael was previously the Fund’s Head of Infrastructure & Timberland where he was responsible for establishing both the Infrastructure & Timberland investment programs.

‍

Raphael is also Chairman of the Investment Committee and a Board Member of the Melbourne Lord Mayor’s Charitable Foundation, Australia’s largest community foundation.

‍

Raphael started his career as an Engineer working with Ove Arup & Partners in Melbourne and London.

‍

He holds Engineering and Economics degrees and a PhD from the University of Melbourne which focused on risk allocation in Public Private Partnerships.

‍

Raymond McCauley is a scientist, engineer, and entrepreneur working at the forefront of biotechnology. Raymond explores how applying technology to life — biology, genetics, medicine, agriculture, manufacturing  — is affecting every one of us. He uses storytelling and down-to-earth examples to show how quickly these changes are happening, right now, and where it may head tomorrow. His work and profile have been featured in Wired, Forbes, Time, CNBC, Science, and Nature.

‍

Raymond is: Founding Faculty and Chair of Digital Biology at Singularity University (http://singularityu.org/); Co-founder and Chief Architect for BioCurious (http://biocurious.org/); part of the team that developed next generation DNA sequencing at Illumina (NASDAQ: ILMN, www.illumina.com), with past positions at Ingenuity Systems, Genome rates, NASA, and other agencies. Raymond creates, advises, and develops biotech-related startups.

Matt Comyn is the Chief Executive Officer and Managing Director of the Commonwealth Bank of Australia.

‍

Matt has 20 years’ experience in banking across business, institutional, retail and wealth management and has held a number of senior leadership roles since joining CBA in 1999, including Group Executive Retail Banking Services and Managing Director of CommSec.

‍

Since becoming CEO in 2018, Matt has been focused on building a simpler bank fully aligned to meeting the needs of customers in core markets, underpinned by stronger risk management and a continuing commitment to innovation and customer service.

‍

Matt holds an Executive MBA from Sydney University, a Master’s degree in Commerce and a Bachelor’s degree in Aviation, both from the University of New South Wales. He has completed the General Management Program at Harvard Business School and is also a director of Unicef Australia.

‍

He is married with three children and lives in Sydney.

‍

Mike Milken has been at the forefront of successful initiatives in medical research, public health, education, and access to capital for more than four decades. Starting as a financier in 1969, he revolutionized modern capital markets by pricing and rewarding risk more efficiently. The thousands of companies he financed created millions of jobs, and a Washington Post article said Milken “helped create the conditions for America’s explosion of wealth and creativity” in the late 20th century.

‍

In 1982 he formalized his previous philanthropy by co-founding the Milken Family Foundation. Fortune magazine called him “The Man Who Changed Medicine” and Forbes listed him among “Visionaries Reimagining Our Children’s Future.” He is chairman of the Milken Institute, which hosts more than 250 events each year including major conferences in Singapore, London, the Middle East, New York, Los Angeles and Washington, D.C. The Milken Institute School of Public Health at George Washington University was named to recognize an Institute gift. FasterCures, one of eight Milken Institute centers, speeds progress against all life-threatening diseases. The Center for Financial Markets promotes financial literacy, access to capital, stronger markets and innovative financial solutions.

‍

A graduate of the University of California, Berkeley, he earned his MBA at the Wharton School of the University of Pennsylvania. He and his wife, Lori, who are members of the Giving Pledge, have been married since 1968; they have three children and 10 grandchildren. More information is at www.mikemilken.com.

Misty Jenkins is a NHMRC fellow and laboratory head in the Immunology Division at Walter and Eliza Hall Institute for Medical Research. Misty leads the immunotherapy program within the Brain Cancer Centre and is dedicated to discovering novel immunotherapy targets for high grade gliomas in adults and children. Her research focusses on the development of novel chimeric antigen receptor T cells for brain cancer. Her group also uses cutting edge two-photon microscopy combined with mouse models of brain cancer to investigate the tumour microenvironment and uncover unique biology of brain tumours.

Misty has a PhD in Immunology from The University of Melbourne, followed by postdoctoral positions at The Universities of Oxford, Cambridge and the Peter MacCallum Cancer Centre.  

Prof Jenkins was awarded the L’Oreal for Women in Science Fellowship (2013), was Tall Poppy of the year (2015), was awarded the Top100 Women of Influence award (2016) and was inducted onto the Victorian Honour Roll of Women in 2020.

‍

In addition to her research career, Prof Jenkins is experienced in governance and strategy as a company Director, co-chairs a Federal Health Medical Research Future Fund (MRFF) and is a passionate advocate for gender equity and Indigenous Health and education. She was awarded an Officer of the Order of Australia (AO) in 2023 for distinguished service to medical science in Immunology, the support of women in STEM, and to the Indigenous community.

Matt was a professional Australian Cricket representative and spent five years at the Victorian Institute of Sport as a coach and player, until injury forced his retirement - turning his attention to business.

With multiple successful exits, Matt has been involved with many high growth digital ventures in Australia, USA & UK in varying roles from founder, executive, to advisor, corporate development lead, investor and board member.

Matt Co-Founded Unlockd, a transformational venture that in ~3 years went from concept to $20m+ ARR (and a $200m market cap) nearly reaching ASX listing before interference by Google after launching in multiple markets internationally including USA, UK, India, Indonesia, Australia and UAE.

Currently, Matt is the Co-Founder and Managing Partner of RealVC - an Early Stage Technology Venture Capital Fund.

Matt is also the Chair of Mental Health Australia, the peak body representing the mental health sector and wider community.

Sharif el Khazen is the founder and Chief Investment Officer of Metronome Capital LLP, a London-based equity investment manager established in 2012. Metronome employs a fundamental, concentrated and long-term investment approach focusing primarily on European stocks.

‍

Prior to founding Metronome, Sharif was a Partner at Parvus Asset Management (UK) LLP from 2006 to 2011. Previously, Sharif was a leveraged finance analyst at Lehman Brothers' investment banking division in London from 2004 to 2006.

‍

Sharif has a Bachelor of Science in Computer Engineering and Computer Science and a Bachelor of Science in Economics/Mathematics from the University of Southern California. Sharif has been a CFA Charterholder since 2008.

Dr Anita Ayer completed her Bachelor of Arts (French and Politics) alongside a Bachelor of Advanced Science (Hons Class I), and was awarded the University Medal in Medical Microbiology and Immunology before receiving her PhD in Biochemistry and Molecular Genetics in 2012 from the University of New South Wales. During her PhD under the mentorship of Prof Ian Dawes, Dr Ayer studied the genetic basis of how cells maintained their redox state and the role of antioxidant using microbial model organisms.

‍

In 2013 she joined the Vascular Biology Laboratory at the Victor Chang Cardiac Research Institute and in 2016 was promoted to Senior Post-Doctoral Scientist and is also a conjoint lecturer at the University of New South Wales. Dr Ayer has a passion for understanding how cells work and using innovative approaches to scientific discovery.

‍

At the Victor Chang Cardiac Research Institute Dr Ayer has been using her expertise in redox biology and biochemistry, and genome-wide screening to study the processes that underlie vascular diseases. Dr Ayer’s currently studies the lipid coenzyme Q, and how coenzyme Q levels can be increased in diseases such as heart failure, atherosclerosis and diabetes to treat and or prevent disease.

‍

Dr Ayer is an inspiration to young women in science and demonstrates the tenacity and determination that is required to succeed in the field of medical research

Mike Cannon-Brookes is the co-founder and co-CEO of Atlassian, a collaboration software company that helps teams organise, discuss and complete shared work. More than 89,000 large and small organisations around the world use Atlassian’s tracking, collaboration, communication, service management and development products to work smarter and faster every day.

‍

Mike has received international recognition for his work, including Ernst & Young’s Australian Entrepreneur Of The Year in 2006 and Australian Business Person of the Year by the Australian Financial Review in 2017. He’s also been honoured by the World Economic Forum as a Young Global Leader in 2009 and was named on the 2017 Forbes Global Game Changers list for reshaping the business world.

‍

Outside Atlassian, Mike is an active angel investor and a non-executive director of Tyro, a technology-focused Australian bank. He serves as an adjunct professor at the University of New South Wales’ School of ComputerScience and Engineering, as well as chair of the Computer Science and Engineering Industry Advisory Board.

‍

Mike holds a Bachelor of Commerce in information systems from the University of New South Wales, Australia.

Philip King is the Chief Investment Officer and co-founder of Regal Funds Management.
‍

Founded in 2004, Regal Funds Management is a multi-award winning specialist alternatives investment manager, with offices located in Sydney and Singapore. The business manages over $3bn in capital on behalf of institutions, family offices, charities and private investors.
‍

Philip is widely recognised as a pioneer of the Australian alternative investment industry, having successfully launched and managed absolute return vehicles at Regal for over 17 years. In 2019, Philip was inducted into the Australian Fund Managers Hall of Fame.

Atul Lele is a Senior Portfolio Strategist and Head of the Portfolio Strategist Group at Bridgewater Associates. A senior member of the research group, Atul works closely with our Co-CIOs, and partners with Bridgewater’s clients on their most important investment priorities, including understanding their goals, developing investment strategies, and providing insight into the research group’s thinking on global markets and economic conditions.

‍

Atul is a 20+ year investment industry veteran. His prior roles include serving as the CIO of Deltec International Group, the Head of Strategy, Economics and Quantitative Research for Credit Suisse Australia, and as a Portfolio Manager and Partner at White Funds Management. Atul is on the Investment Advisory Group of the Australian Consul General in New York and has regularly appeared in the financial media. He is a CFA charterholder and holds a Bachelor of Commerce in Accounting and Finance from the University of New South Wales.

Ed Cowan is a member of the Investment Team at TDM Growth Partners and a Core Fund Manager for HM1. TDM Growth Partners is a global investment firm, investing in a portfolio of 10-15 fast growing public and private companies.

‍

Having travelled the world playing professional cricket for over 15 years, Ed joined his brother Tom at TDM in 2018. Ed is involved in many parts of TDM, supporting portfolio companies and their executives, leading TDM’s platform-building efforts, and helping create and nurture the best possible investment opportunities across TDM's investment landscape.

‍

Ed holds a Bachelor of Commerce (Accounting and Finance) from Sydney University, a Masters of Applied Finance form Macquarie University, and currently sits on the Board of Cricket NSW.

‍

Jun Bei Liu is the Portfolio Manager of Tribeca’s Alpha Plus Fund. Since taking over sole responsibility for managing the Fund, she has quadrupled AUM. She is a passionate, motivated, and dedicated investment manager having built an 18-year career at Tribeca, starting as an equity analyst in 2005 and spending several years as a Portfolio Manager, before taking over the Alpha Plus Fund in 2019.

Jun Bei completed a commerce degree at the University of NSW, followed by a number of additional finance credentials including GAICD and CFA. She is a prolific contributor to Australia’s financial services sector, writing a regular column for the AFR and making frequent appearances for key media outlets and as a speaker at industry events. Jun Bei enjoys sharing her knowledge and love for markets with investors and promotes the growth of like-minded females within the financial services community by providing mentor opportunities and serving on the advisory committee for Australian Student Asset Management. Jun Bei is a TEDX speaker, has been appointed as a Core Fund Manager for Hearts and Minds Investments Ltd (HM1) and volunteers for the Raise Foundation Board.

She is fluent in Mandarin and English, only learning English as a 16-year-old, when she emigrated to Australia from China.

Commencing his career as a chartered accountant, Chris Cuffe entered the funds management industry in 1985. In 1988 he joined Colonial First State where he was CEO from 1990 until 2003. In 2003 he became CEO of the listed Challenger Group.

‍

Chris is now involved in a portfolio of activities in the investment and non-profit sectors. In addition to being Chairman of Hearts and Minds Investments, this includes:

• Investment Committee member of UniSuper and the Paul Ramsay Foundation;
• Chairman of Australian Philanthropic Services and portfolio manager of the APS Foundation;
• Director of Global Value Fund, Argo Investments, Keyview Financial Group;
• Founder, Director and Portfolio Manager of Third Link Growth Fund.

‍

Chris holds a Bachelor of Commerce from the University of NSW and a Diploma from the Securities Institute of Australia (now the Financial Services Institute of Australasia). He is a Fellow of the Institute of Chartered Accountants in Australia, a Fellow of the Institute of Company Directors and an Associate of the Financial Services Institute of Australasia. In 2007 Chris was inducted into the Australian Fund Manager’s RBS Hall of Fame for services to the investment industry. In 2017 he was appointed as an Officer in the General Division of the Order of Australia.

Professor Daniel MacArthur is the Director of the Centre for Population Genomics (CPG), a joint initiative of the Garvan Institute of Medical Research in Sydney and the Murdoch Children’s Research Institute in Melbourne. The CPG was established to solve the critical scientific, regulatory, and technical problems currently limiting the development of genomic medicine in Australia, and to execute large-scale projects that will establish Australia’s leadership in this field.

‍

Daniel previously served as Co-Director of the Medical and Population Genetics Program at the Broad Institute of MIT and Harvard, and headed up a team jointly based at the Broad Institute, Massachusetts General Hospital, and Harvard Medical School. He co-directed the Broad Institute's Centre for Mendelian Genomics, which has sequenced and analysed genomic data from over 10,000 individuals from rare disease families and contributed to the discovery of more than 100 new rare disease genes. He also led the development of the Genome Aggregation Database (gnomAD), the largest and most widely-used data set of human exome and genome sequence data, which has collated data from over 140,000 sequenced individuals.

Anthony is the Portfolio Manager of Industrial Shares, SHARE-PLUS Long-Short and Co-Portfolio Manager of Perpetual Pure Equity Alpha.

Anthony has been with Perpetual for 10 years. Prior to joining Perpetual, he worked at Ellerston Capital for 6 years, where he was the Portfolio Manager for the Ellerston Capital Global Equity Management Fund for 2 years. Before that, he spent 4 years as an Analyst working on a long/short strategy. Prior to joining Ellerston Capital, Anthony worked as an Analyst at UBS Investment Bank for 8 years.

Anthony has a Bachelor of Economics from the University of Sydney and has earned the right to use the Chartered Financial Analyst designation.